Functional epigenetic approach identifies frequently methylated genes in Ewing sarcoma

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Ewing sarcoma (ES) is a rare bone cancer with limited therapeutic options.
• Identifying reliable biomarkers for prognosis and detection in ES is crucial.
• Previous studies identified RASSF2 gene methylation associated with poor survival in ES.

Purpose of the Study:

• To identify genome-wide epigenetic biomarkers for Ewing sarcoma (ES).
• To investigate gene methylation patterns and their association with prognosis in ES.
• To explore potential biomarkers for osteosarcoma as well.

Main Methods:

• Utilized a demethylating agent to induce gene expression in ES cell lines.
• Employed high-density gene expression microarrays for genome-wide analysis.
• Performed expression and methylation analysis on ES cell lines and primary tumors.

Main Results:

• Eight genes (CTHRC1, DNAJA4, ECHDC2, NEFH, NPTX2, PHF11, RARRES2, TSGA14) showed >20% methylation in ES tumors.
• Hypermethylation correlated with transcriptional silencing and was observed in mesenchymal stem cells.
• Methylation of NPTX2 or PHF11 was associated with poorer prognosis in ES.
• Six genes also exhibited >20% methylation in osteosarcomas.

Conclusions:

• Identified novel genes with frequent methylation in ES, potentially serving as prognostic and diagnostic biomarkers.
• These findings offer insights into bone cancer tumorigenesis.
• The identified epigenetic markers may aid in the detection and management of rare bone tumors.